Goldman Sachs’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Goldman Sachs’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,173	Closed	-$53K	–	7125
2017 Q1	$53K	Buy	2,173 +2,148	+8,592%	+$53.7K	﹤0.01%	6271
2016 Q4	$1K	Buy	+25	New	+$1.07K	﹤0.01%	6862
2016 Q3	–	Sell	-25	Closed	-$1K	–	7333
2016 Q2	$1K	Sell	25 -9,596	-100%	-$523K	﹤0.01%	6997
2016 Q1	$634K	Buy	+9,621	New	+$502K	﹤0.01%	4508
2015 Q4	–	Sell	-14,553	Closed	-$974K	–	7532
2015 Q3	$974K	Buy	+14,553	New	+$1.19M	﹤0.01%	4515
2014 Q3	–	Sell	-31,775	Closed	-$1.82M	–	7385
2014 Q2	$1.82M	Sell	31,775 -48,959	-61%	-$2.49M	﹤0.01%	4082
2014 Q1	$3.2M	Buy	+80,734	New	+$3.45M	﹤0.01%	3529

Goldman Sachs's MACK Position: Q3 2024 in Review

Goldman Sachs sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2024, closing a stake of 29,807 shares — an estimated $451K sold.

Goldman Sachs first reported a position in MACK in Q2 2013 and held it in 32 quarters. The position peaked at $4.8M in Q2 2014. 2 funds tracked by Wall St. Rank hold MACK as of Q3 2024.

Goldman Sachs reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
Goldman Sachs sold 29,807 Merrimack Pharmaceuticals, Inc. shares in Q3 2024, an estimated $451K.
Goldman Sachs first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
Goldman Sachs's Merrimack Pharmaceuticals, Inc. position peaked at $4.8M in Q2 2014.
2 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.